Cardiovascular benefits can increase Rybelsus’ competitiveness over other oral GLP-1RAs
The market for oral GLP-1RAs is expanding, and Rybelsus’ latest results showed its benefits in reducing the risk in cardiovascular…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ozempic
US FDA flags dosing risks from compounded versions of Novo’s weight-loss drug
Regulator highlights risks of dosing errors and adverse events, urges healthcare providers to ensure correct syringe use and…
Ozempic linked with lower dementia risk, nicotine use, British study finds
The study, published in the Lancet's eClinicalMedicine journal, explored more than 100 million medical records of the U.S.…
WHO issues warnings on fake copies of Novo Nordisk’s weight-loss drugs
The warnings were issued on fake drugs claiming to contain the active ingredient found in Novo Nordisk's diabetes drug Ozempic…
GLP1 agonists set to become the best-selling drugs in 2024: GlobalData
Shift could reflect a changing demand away from oncology toward addressing metabolic disorders
Catalent to help Novo Nordisk address production demands for Ozempic and Wegovy: GlobalData
The acquisition of Catalent by Novo Holdings expects to see three new manufacturing sites added to Novo Nordisk’s arsenal, to…
US FDA approves Novo Nordisk’s Ozempic 2 mg to treat type-II diabetes
Ozempic demonstrated 2.1 per cent blood sugar reduction and also weight loss in adults with type-II diabetes with new 2 mg dose
Global diabetes therapeutic market has grown sixfold in last two decades: GlobalData
The market has been a lucrative space for drug developers, as the disease is highly prevalent and patient numbers are expected to…
T2D market will grow from a total of $48.1bn sales in 2019 to $91.9 bn in 2029
T2D market growth factors are increasing diagnosed prevalence of disease and the emergence of novel pipeline agents